JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIM

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This study aims to investigate the clinical efficacy of baricitinib in patients with adult idiopathic inflammatory myositis (IIM). Half of the patients enrolled onto the study will receive 24 weeks of baricitinib from the baseline visit with a 12 week follow-up period. The other half of patients will receive 24 weeks of barcitinib treatment after an initial 12-week delay with a 4 week follow up period for safety.
Epistemonikos ID: 09e04e74bfd4d7228e46761fae8148304d1b8e36
First added on: May 06, 2024